Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug - Reuters
4:55am PST - March 1st, 2021 merck - ReutersGermany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.